イリノイ州における膠腫の臨床試験
イリノイ州内の拠点で、膠腫に関する13件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- University of Chicago Comprehensive Cancer Center, Chicago
- OSF Children's Hospital of Illinois, Peoria
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
3歳〜39歳 · 全性別 · 2026/08/24更新 · NCT05096481Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/08/18更新 · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/12更新 · NCT05417594A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- Northwestern Medicine, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07464925MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第1/2相
1歳〜26歳 · 全性別 · 2026/07/10更新 · NCT06712875Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06810544rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第1相
12 Months – 18 Years · 全性別 · 2026/03/17更新 · NCT04943848ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。